Summary

Africa pharmaceutical molecules market is expected to reach USD 26.71 billion by 2032 from USD 13.48 billion in 2024, growing at a CAGR of 9.03% in the forecast period of 2025 to 2032.
Market Segmentation:
Africa Pharmaceutical Molecules Market, By Type (Nervous System, Anti-Infectives for Systemic Use, Cardiovascular System, Anti-Neoplastic and Immunomodulating Agents, Alimentary Tract & Metabolism, Musculo-Skeletal System, Genito-Urinary System and Sex Hormones, Respiratory System, Blood and Blood Forming Agents, and Vaccines), Dosage Form (Oral and Injectables), Potency (Traditional Potency and High-Potency), Manufacturing Method (In-House Manufacturing and Contract Manufacturing), Age Group (Adult, Pediatric, and Geriatric), Distribution Channel (Direct Tenders, Retail Sales, and Others), Country (Angola, Botswana, Eswatini (Formerly Swaziland), Lesotho, Malawi, Dr Congo (Kinshasa), Namibia, Madagascar, Mauritius, Seychelles, Comoros, Tanzania, South Africa, Zambia, Zimbabwe, Mozambique, Eritrea, Djibouti, Somalia, Kenya, Burundi, Rwanda, Uganda, South Sudan, Sudan, Ethiopia, Gabon, Congo (Brazzaville), Central Africa Republic, Guinea Equatorial, Cameroun, Chad, Burkina Faso, Niger, Nigeria, Togo, Guinea Bissau, Guinea Republic, Senegal, Sierra Leone, Liberia, Cote D'ivoire, Ghana, Mali, Cape Verde, and Mauritania) - Industry Trends & Forecast To 2032


Overview of Africa Pharmaceutical Molecules Market Dynamics:

Driver

• Advancements In Technology Enhance Healthcare Service Delivery
Restraint

• Heavy Reliance On Imports Increases Market Vulnerability
Opportunity

• Strengthening Collaboration Between Public-Private Sector Partnerships

Market Players:

The key market players operating in the Africa pharmaceutical molecules market are listed below:

• Pfizer, Inc.
• Aspen Holdings
• Johnson & Johnson Services, Inc.
• Novartis AG
• Sanofi
• GSK Plc (GlaxoSmithKline)
• Merck KGaA
• AstraZeneca
• Cipla
• Advacare Pharma
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd.
• Ferring Pharmaceuticals
• Adcock Ingram
• Pharma Deko Plc
• Ranbaxy Nigeria Limited
• Swiss Pharma Nigeria Limited (Swipha)
• Bayer AG

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE AFRICA PHARMACEUTICAL MOLECULES MARKET 21
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 24
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 DBMR TRIPOD DATA VALIDATION MODEL 33
2.3 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.4 DBMR MARKET POSITION GRID 38
2.5 VENDOR SHARE ANALYSIS 39
2.6 SECONDARY SOURCES 40
2.7 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 45
4.1 PORTER’S FIVE FORCES 46
5 AFRICA PHARMACEUTICAL MOLECULES MARKET: REGULATIONS 48
5.1 REGULATORY FRAMEWORK FOR AFRICA PHARMACEUTICAL MOLECULES MARKET 48
5.2 NATIONAL MEDICINES REGULATORY AUTHORITIES (NMRAS) 48
5.3 EAST AFRICAN COMMUNITY (EAC) MEDICINES REGULATORY HARMONIZATION 49
5.4 ECONOMIC COMMUNITY OF WEST AFRICAN STATES (ECOWAS) MEDICINES REGULATORY HARMONIZATION 49
5.5 SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) MEDICINES REGULATORY FRAMEWORK 50
6 MARKET OVERVIEW 52
6.1 DRIVERS 54
6.1.1 REGULATORY IMPROVEMENTS CREATE FAVORABLE MARKET ENVIRONMENTS 54
6.1.2 ADVANCEMENTS IN TECHNOLOGY ENHANCE HEALTHCARE SERVICE DELIVERY 54
6.1.3 PHARMACEUTICAL MANUFACTURING GROWTH FOSTERS LOCAL PRODUCTION CAPABILITIES 55
6.1.4 RISING MIDDLE CLASS SPARKS RAPID URBANIZATION ACROSS AFRICA 56
6.2 RESTRAINTS 57
6.2.1 HEAVY RELIANCE ON IMPORTS INCREASES MARKET VULNERABILITY 57
6.2.2 LIMITED RESEARCH AND DEVELOPMENT INFRASTRUCTURE HAMPERS INNOVATION 57
6.3 OPPORTUNITIES 58
6.3.1 GOVERNMENT AND FOREIGN INVESTMENTS PROMOTING PHARMACEUTICAL INDUSTRY GROWTH 58
6.3.2 STRENGTHENING COLLABORATION BETWEEN PUBLIC-PRIVATE SECTOR PARTNERSHIPS 59
6.3.3 RISING DEMAND FOR CHRONIC DISEASE TREATMENT SOLUTIONS 59
6.4 CHALLENGES 60
6.4.1 HIGH COSTS OF PHARMACEUTICAL MOLECULES PRODUCTION 60
6.4.2 LIMITED SKILLED WORKFORCE IN PHARMACEUTICAL INDUSTRY 61
7 AFRICA PHARMACEUTICAL MOLECULES MARKET, BY TYPE 62
7.1 OVERVIEW 63
7.2 NERVOUS SYSTEM 67
7.2.1 PARACETAMOL SOLUTION FOR INFUSION 68
7.2.2 ESCITALOPRAM FILM-COATED TABLETS 68
7.2.3 PREGABALIN CAPSULES 68
7.2.4 GABAPENTIN TABLET AND CAPSULES 68
7.2.5 SERTRALINE FILM-COATED TABLETS 68
7.2.6 ARIPIPRAZOLE TABLETS 68
7.2.7 OLANZAPINE FILM-COATED TABLETS 68
7.2.8 RISPERIDONE TABLETS 1MG 68
7.2.9 DONEPEZIL FILM-COATED TABLETS 68
7.2.10 LORAZEPAM FILM-COATED TABLETS 68
7.2.11 ATOMOXETINE TABLET AND SOLUTION 68
7.2.12 MIRTAZAPINE FILM-COATED TABLETS 68
7.2.13 LEVETIRACETAM 68
7.2.14 TOPIRAMATE FILM-COATED TABLETS 68
7.2.15 MEMANTINE FILM-COATED TABLETS 68
7.2.16 CINNARIZINE + DIMENHYDRINATE FILM-COATED TABLETS 68
7.2.17 OXCARBAZEPINE TABLETS 68
7.2.18 VORTIOXETINE FILM-COATED TABLETS 68
7.2.19 LACOSAMIDE TABLETS 68
7.2.20 LACOSAMIDE SYRUP 68
7.2.20.1 20 MG 72
7.2.20.2 5 MG 72
7.2.20.3 10 MG 72
7.2.21 GABAPENTIN FILM-COATED TABLETS 72
7.2.22 GABAPENTIN CAPSULES 72
7.2.22.1 800 MG 73
7.2.22.2 600 MG 73
7.2.23 400 MG 73
7.2.24 300 MG 73
7.2.25 100 MG 73
7.2.26 100 MG 74
7.2.27 50 MG 74
7.2.27.1 ARIPIPRAZOLE TABLETS (VARIOUS STRENGTHS) 74
7.2.27.2 ARIPIPRAZOLE ORODISPERSIBLE TABLETS (VARIOUS STRENGTHS) 74
7.2.28 10 MG 75
7.2.29 5 MG 75
7.2.29.1 ATOMOXETINE TABLETS (VARIOUS STRENGTHS) 75
7.2.29.2 ATOMOXETINE ORAL SOLUTION 75
7.2.29.2.1 LEVETIRACETAM FILM-COATED TABLETS 76
7.2.29.2.2 LEVETIRACETAM ORAL SYRUP (VARIOUS STRENGTHS) 76
7.2.30 20 MG 76
7.2.31 5 MG 76
7.2.32 10 MG 76
7.2.32.1 600 MG 77
7.2.32.2 300 MG 77
7.2.32.2.1 200 MG 77
7.2.32.2.2 150 MG 77
7.2.32.2.3 100 MG 77
7.2.32.2.4 50 MG 77
7.3 ANTI-INFECTIVES FOR SYSTEMIC USE 78
7.3.1 AZITHROMYCIN POWDER FOR SOLUTION FOR INFUSION: 500MG 78
7.3.2 LEVOFLOXACIN FILM-COATED TABLETS 78
7.3.3 FLUCONAZOLE CAPSULE 78
7.3.4 VALACICLOVIR FILM-COATED TABLETS 78
7.3.5 TIGECYCLINE POWDER FOR SOLUTION FOR INFUSION: 5MG/5ML 79
7.3.5.1 500MG 80
7.3.5.2 250MG 80
7.3.5.2.1 150 MG 81
7.3.5.2.2 50 MG 81
7.3.5.2.3 200 MG 81
7.3.5.2.4 OTHERS 81
7.3.5.2.4.1 500 MG 81
7.3.5.2.4.2 1000 MG 81
7.4 CARDIOVASCULAR SYSTEM 82
7.4.1 AMLODIPINE TABLETS 83
7.4.2 ATORVASTATIN FILM-COATED TABLETS 83
7.4.3 LOSARTAN 83
7.4.4 ROSUVASTATIN FILM-COATED TABLETS 83
7.4.5 VALSARTAN FILM-COATED TABLETS 83
7.4.6 CARVEDILOL TABLETS 83
7.4.7 IRBESARTAN 83
7.4.8 CHLORTALIDONE TABLETS 83
7.4.9 EZETIMIBE 83
7.4.10 PERINDOPRIL + INDAPAMIDE TABLETS 83
7.4.11 TELMISARTAN TABLETS 83
7.4.12 PITAVASTATIN FILM-COATED TABLETS 83
7.4.13 SILDENAFIL FILM-COATED TABLETS (20MG) 83
7.4.14 VALSARTAN + HYDROCHLOROTHIAZIDE (HCTZ) TABLETS 83
7.4.15 EPLERENONE FILM-COATED TABLETS 83
7.4.16 MACITENTAN FILM-COATED TABLETS (10MG) 83
7.4.16.1 5 MG 86
7.4.16.2 10 MG 86
7.4.16.2.1 10 MG 86
7.4.16.2.2 20 MG 86
7.4.16.2.3 40 MG 87
7.4.16.2.4 LOSARTAN FILM-COATED TABLETS 87
7.4.16.2.5 LOSARTAN + HCTZ FILM-COATED TABLETS 87
7.4.16.2.5.1 10 MG 87
7.4.16.2.5.2 20 MG 87
7.4.16.2.5.3 5 MG 88
7.4.16.2.6 80 MG 88
7.4.16.2.7 160 MG 88
7.4.16.2.8 40 MG 88
7.4.16.2.9 120 MG 88
7.4.16.2.9.1 6.25 MG 88
7.4.16.2.9.2 25 MG 89
7.4.16.3 IRBESARTAN FILM-COATED TABLETS 89
7.4.16.4 IRBESARTAN + HCTZ FILM-COATED TABLETS 89
7.4.16.5 150 MG 89
7.4.16.6 75 MG 89
7.4.16.7 300 MG 90
7.4.16.7.1 300 MG+12.5 MG 90
7.4.16.7.2 150 MG+12.5 MG 90
7.4.16.7.3 300 MG+25 MG 90
7.4.16.7.3.1 12.5 MG 90
7.4.16.7.3.2 25 MG 90
7.4.16.7.3.3 50 MG 91
7.4.17 EZETIMIBE + SIMVASTATIN FILM-COATED 91
7.4.18 EZETIMIBE + ROSUVASTATIN CAPSULE 91
7.4.19 EZETIMIBE FILM-COATED TABLETS 91
7.4.19.1 10 MG + 10 MG 91
7.4.19.2 10 MG + 20 MG 91
7.4.19.3 10 MG + 40 MG 92
7.4.19.3.1 10 MG + 10 MG 92
7.4.19.3.2 10 MG + 20 MG 92
7.4.19.3.3 10 MG + 5 MG 92
7.4.19.3.3.1 25 MG 92
7.4.19.3.3.2 50 MG 93
7.4.19.3.4 4 MG + 1.25 MG 93
7.4.19.3.5 8 MG + 2.5 MG 93
7.4.19.3.6 2 MG + 0.625 MG 93
7.4.19.3.6.1 20 MG 93
7.4.19.3.6.2 40 MG 93
7.4.19.3.6.3 80 MG 94
7.4.19.4 4 MG 94
7.4.19.5 2 MG 94
7.4.19.6 1 MG 94
7.4.19.6.1 360 MG + 25 MG 94
7.4.19.6.2 80 MG + 12.5 MG 94
7.4.19.6.3 160 MG + 25 MG 94
7.4.19.6.4 160 MG + 12.5 MG 94
7.4.19.6.5 320 MG + 12.5 MG 95
7.4.19.6.5.1 25 MG 95
7.4.19.6.5.2 50 MG 95
7.5 ANTI-NEOPLASTIC AND IMMUNOMODULATING AGENTS 96
7.5.1 ABIRATERONE 96
7.5.2 TAMOXIFEN 96
7.5.3 BICALUTAMIDE 96
7.5.4 LENALIDOMIDE 96
7.5.5 BORTEZOMIB 96
7.5.6 MYCOPHENOLATE MOFETIL 96
7.5.7 SUNITINIB 97
7.5.8 LETROZOLE 97
7.5.9 PALBOCICLIB 97
7.5.10 TERIFLUNOMIDE 97
7.5.11 DIMETHYL FUMARATE 97
7.5.12 LEFLUNOMIDE 97
7.5.13 PIRFENIDONE 97
7.5.14 POMALIDOMIDE 97
7.5.15 FINGOLIMOD 97
7.5.15.1 250MG 99
7.5.15.2 500MG 99
7.5.15.2.1 10MG 99
7.5.15.2.2 20MG 99
7.5.15.2.3 50MG 100
7.5.15.2.4 50MG 100
7.5.15.2.4.1 7MG 100
7.5.15.2.4.2 14MG 100
7.5.15.2.5 10MG 100
7.5.15.2.6 20MG 100
7.6 ALIMENTARY TRACT & METABOLISM 101
7.6.1 SITAGLIPTIN TABLETS 101
7.6.2 EMPAGLIFLOZIN TABLETS 101
7.6.3 DAPAGLIFLOZIN TABLETS 101
7.6.4 ONDANSETRON INJECTION – 4MG/8MG 101
7.6.5 VILDAGLIPTIN TABLETS – 50MG 102
7.6.6 PANTOPRAZOLE INJECTION – 40MG 102
7.6.7 PIOGLITAZONE TABLETS 102
7.6.8 ESOMEPRAZOLE INJECTION – 40MG 102
7.6.9 CANAGLIFLOZIN TABLETS 102
7.6.10 ACARBOSE TABLETS 102
7.6.10.1 SITAGLIPTIN FILM-COATED TABLETS (VARIOUS STRENGTHS) 104
7.6.10.2 SITAGLIPTIN + METFORMIN FILM-COATED TABLETS (VARIOUS COMBINATIONS) 104
7.6.10.2.1 EMPAGLIFLOZIN FILM-COATED TABLETS 105
7.6.10.2.2 EMPAGLIFLOZIN + METFORMIN FILM-COATED TABLETS (VARIOUS COMBINATIONS) 105
7.6.10.2.3 EMPAGLIFLOZIN + LINAGLIPTIN TABLETS (VARIOUS COMBINATIONS) 105
7.6.10.2.3.1 10 MG 105
7.6.10.2.3.2 25 MG 105
7.6.10.3 10 MG 105
7.6.10.4 5 MG 106
7.6.10.4.1 PIOGLITAZONE TABLETS VARIOUS STRENGTHS 106
7.6.10.4.2 PIOGLITAZONE + METFORMIN COATED TABLETS (VARIOUS COMBINATIONS) 106
7.6.10.4.2.1 CANAGLIFLOZIN FILM-COATED TABLETS 107
7.6.10.4.2.2 CANAGLIFLOZIN + METFORMIN FILM-COATED TABLETS (VARIOUS COMBINATIONS) 107
7.6.10.5 300 MG 107
7.6.10.6 100 MG 107
7.6.10.6.1 50MG 107
7.6.10.6.2 100MG 107
7.7 MUSCULO-SKELETAL SYSTEM 108
7.7.1 ETORICOXIB FILM-COATED TABLETS 108
7.7.2 CELECOXIB CAPSULES 108
7.7.3 ALENDRONIC ACID FILM-COATED TABLETS 70 MG 108
7.7.4 FEBUXOSTAT FILM-COATED TABLETS 108
7.7.5 IBANDRONIC ACID FILM-COATED TABLETS 150 MG 108
7.7.5.1 100 MG 110
7.7.5.2 200 MG 110
7.7.5.2.1 80 MG 110
7.7.5.2.2 120 MG 110
7.7.5.2.2.1 50 MG 111
7.7.5.2.2.2 150 MG 111
7.8 GENITO-URINARY SYSTEM AND SEX HORMONES 111
7.8.1 SILDENAFIL FILM-COATED TABLETS 111
7.8.2 TADALAFIL FILM-COATED TABLETS 111
7.8.3 FINASTERIDE FILM-COATED TABLETS 111
7.8.4 SILODOSIN FILM-COATED TABLETS 111
7.8.5 SOLIFENACIN FILM-COATED TABLETS 111
7.8.6 MIRABEGRON PROLONGED-RELEASE TABLETS 111
7.8.6.1 8 MG 113
7.8.6.2 4 MG 113
7.8.6.2.1 5MG 113
7.8.6.2.2 10MG 113
7.8.6.2.2.1 50MG 114
7.8.6.2.2.2 25MG 114
7.9 RESPIRATORY 114
7.9.1 MONTELUKAST FILM-COATED TABLETS: 10MG 114
7.9.2 OTHERS 115
7.10 BLOOD AND BLOOD FORMING AGENTS 116
7.10.1 CLOPIDOGREL FILM-COATED TABLETS 75MG 116
7.10.2 CLOPIDOGREL + ASA HARD-COATED TABLETS 116
7.10.3 APIXABAN FILM-COATED TABLETS 116
7.10.4 RIVAROXABAN FILM-COATED TABLETS 116
7.10.5 TICAGRELOR FILM-COATED TABLETS 116
7.10.6 PRASUGREL FILM-COATED TABLETS 116
7.10.6.1 75MG+75MG 118
7.10.6.2 75MG+100MG 118
7.10.6.2.1 5 MG 118
7.10.6.2.2 2.5 MG 118
7.10.6.2.2.1 20MG 119
7.10.6.2.2.2 10MG 119
7.10.6.2.2.3 15MG 119
7.10.6.2.2.4 2.5MG 119
7.10.6.2.3 60MG 119
7.10.6.2.4 90MG 120
7.10.6.2.5 5MG 120
7.10.6.2.6 10MG 120
7.11 VACCINES 120
7.11.1 MMR (MEASLES, MUMPS, RUBELLA) 120
7.11.2 YELLOW FEVER 120
7.11.3 HEPATITIS B 121
7.11.4 HPV (HUMAN PAPILLOMAVIRUS) 121
7.11.5 MALARIA 121
7.11.6 FLU (INFLUENZA) 121
8 AFRICA PHARMACEUTICAL MOLECULES MARKET, BY POTENCY 122
8.1 OVERVIEW 123
8.2 TRADITIONAL POTENCY 126
8.3 HIGH-POTENCY 126
9 AFRICA PHARMACEUTICAL MOLECULES MARKET, MANUFACTURING METHOD 127
9.1 OVERVIEW 128
9.2 IN-HOUSE MANUFACTURING 131
9.3 CONTRACT MANUFACTURING 131
10 AFRICA PHARMACEUTICAL MOLECULES MARKET, BY DOSAGE FORM 132
10.1 OVERVIEW 133
10.2 ORAL 136
10.2.1 TABLET 136
10.2.2 CAPSULES 136
10.2.3 SOLUTION/SYRUPS 136
10.3 INJECTABLES 137
10.3.1 SOLUTION 137
10.3.2 POWDER 137
11 AFRICA PHARMACEUTICAL MOLECULES MARKET, AGE GROUP 138
11.1 OVERVIEW 139
11.2 ADULT 142
11.3 PEDIATRIC 142
11.4 GERIATRIC 142
12 AFRICA PHARMACEUTICAL MOLECULES MARKET, BY DISTRIBUTION CHANNEL 143
12.1 OVERVIEW 144
12.2 DIRECT TENDERS 147
12.3 RETAIL SALES 147
12.3.1 HOSPITAL PHARMACIES 147
12.3.2 DRUG STORES 147
12.3.3 E-PHARMACY 147
12.3.4 OTHERS 147
12.4 OTHERS 147
13 SWOT ANALYSIS 14814 COMPANY PROFILES 149
14.1 ADCOCK INGRAM 149
14.1.1 COMPANY SNAPSHOT 149
14.1.2 REVENUE ANALYSIS 150
14.1.3 PRODUCT PORTFOLIO 150
14.1.4 RECENT DEVELOPMENT 152
14.2 ADVACARE PHARMA 153
14.2.1 COMPANY SNAPSHOT 153
14.2.2 PRODUCT PORTFOLIO 153
14.2.3 RECENT DEVELOPMENT 155
14.3 ASTRAZENECA 156
14.3.1 COMPANY SNAPSHOT 156
14.3.2 REVENUE ANALYSIS 157
14.3.3 PRODUCT PORTFOLIO 157
14.3.4 RECENT DEVELOPMENT 158
14.4 BAYER AG 159
14.4.1 COMPANY SNAPSHOT 159
14.4.2 REVENUE ANALYSIS 159
14.4.3 PRODUCT PORTFOLIO 160
14.4.4 RECENT DEVELOPMENT 161
14.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 162
14.5.1 COMPANY SNAPSHOT 162
14.5.2 REVENUE ANALYSIS 162
14.5.3 PRODUCT PORTFOLIO 163
14.5.4 RECENT DEVELOPMENT 163
14.6 CIPLA 164
14.6.1 COMPANY SNAPSHOT 164
14.6.2 REVENUE ANALYSIS 164
14.6.3 PRODUCT PORTFOLIO 165
14.6.4 RECENT DEVELOPMENT 165
14.7 F. HOFFMANN-LA ROCHE LTD 166
14.7.1 COMPANY SNAPSHOT 166
14.7.2 REVENUE ANALYSIS 166
14.7.3 PRODUCT PORTFOLIO 167
14.7.4 RECENT DEVELOPMENT 167
14.8 FERRING 168
14.8.1 COMPANY SNAPSHOT 168
14.8.2 PRODUCT PORTFOLIO 168
14.8.3 RECENT DEVELOPMENT 169
14.9 GSK PLC. 170
14.9.1 COMPANY SNAPSHOT 170
14.9.2 REVENUE ANALYSIS 171
14.9.3 PRODUCT PORTFOLIO 171
14.9.4 RECENT DEVELOPMENT 173
14.10 JOHNSON & JOHNSON SERVICES, INC. 175
14.10.1 COMPANY PROFILES 175
14.10.2 REVENUE ANALYSIS 175
14.10.3 PRODUCT PORTFOLIO 176
14.10.4 RECENT DEVELOPMENT 177
14.11 MERCK KGAA 178
14.11.1 COMPANY SNAPSHOT 178
14.11.2 REVENUE ANALYSIS 178
14.11.3 PRODUCT PORTFOLIO 179
14.11.4 RECENT DEVELOPMENT 181
14.12 NOVARTIS AG 182
14.12.1 COMPANY SNAPSHOT 182
14.12.2 REVENUE ANALYSIS 183
14.12.3 PRODUCT PORTFOLIO 183
14.12.4 RECENT DEVELOPMENT 184
14.13 PFIZER INC. 186
14.13.1 COMPANY PROFILES 186
14.13.2 REVENUE ANALYSIS 186
14.13.3 PRODUCT PORTFOLIO 187
14.13.4 RECENT DEVELOPMENT 189
14.14 PHARMA DEKHO PLC. 190
14.14.1 COMPANY SNAPSOT 190
14.14.2 PRODUCT PORTFOLIO 190
14.14.3 RECENT DEVELOPMENT 190
14.15 PHARMA DEKHO PLC. 191
14.15.1 COMPANY SNAPSHOT 191
14.15.2 PRODUCT PORTFOLIO 191
14.15.3 RECENT DEVELOPMENT 191
14.16 SANOFI 192
14.16.1 COMPANY SNAPSHOT 192
14.16.2 REVENUE ANALYSIS 192
14.16.3 PRODUCT PORTFOLIO 193
14.16.4 RECENT DEVELOPMENT 194
14.17 SUN PHARMACEUTICAL INDUSTRIES LTD. 195
14.17.1 COMPANY SNAPSHOT 195
14.17.2 REVENUE ANALYSIS 196
14.17.3 PRODUCT PORTFOLIO 196
14.17.4 RECENT DEVELOPMENT 198
14.18 SWISS PHARMA NIGERIA LIMITED 199
14.18.1 COMPANY SNAPSHOT 199
14.18.2 PRODUCT PORTFOLIO 199
14.18.3 RECENT DEVELOPMENT 200
15 QUESTIONNAIRE 201
16 RELATED REPORTS 204